Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 13/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30172477 | 1.00 | MAP2K1 (0.63) | MAP2K1MAP2K2CA2MAPTHTT | |
| SCHEMBL30080395 | 0.87 | MAP2K1 (0.64) | MAP2K1MAP2K2 | |
| SCHEMBL16571357 | 0.87 | MAP2K1 (0.64) | MAP2K1MAP2K2 | |
| SCHEMBL29781352 | 0.84 | MAP2K1 (0.65) | MAP2K1MAP2K2CA2 | |
| SCHEMBL25191479 | 0.83 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL13974077 | 0.83 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL30682848 | 0.83 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL27496434 | 0.83 | MAP2K1 (0.49) | MAP2K1MAP2K2CA2 | |
| SCHEMBL5386714 | 0.82 | IDO1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL31401745 | 0.82 | MAP2K2 (0.66) | MAP2K1MAP2K2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117083264-A | Crystalline solids of the MEK inhibitor N- ((R) -2, 3-dihydroxypropoxy) -3, 4-difluoro-2- (2-fluoro-4-iodo-phenylamino) -benzamide and uses thereof | 斯普林渥克斯治疗股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230330047-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | SPRINGWORKS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| EP-3735247-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 Therapeutics, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019136244-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2008132464-A2 | MEK5 AND RELATED PROTEINS AS BIOMARKERS OF NEURODEGENERATIVE DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2008-11-06 | — | — | WO | disclosed |
| CN-101124199-A | 5-substituted-2-phenylamino-benzamides as MEK inhibiting substances | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-02-13 | — | — | CN | disclosed |
| EP-1301472-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002006213-A2 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330047-A1 | DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- FLUORO-4-IODO-PHENYLAMINO)-BENAZMIDE AND USES THEREOF | QDPR, DHFR, NEFM | MAP2K1 4337/4885MAP2K2 3323/4885CA2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.